Kintara Therapeutics (KTRA)

Kintara Therapeutics (KTRA) Stock Price & Analysis


KTRA Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$2.70 - $20.00
Previous Close$3.26
Average Volume (3M)41.96K
Market Cap
Enterprise Value$2.47M
Total Cash (Recent Filing)$3.04M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-0.3
Sep 25, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.59
Shares Outstanding1,692,175
10 Day Avg. Volume31,601
30 Day Avg. Volume41,956
Standard Deviation0.29
Financial Highlights & Ratios
Price to Book (P/B)1.67
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.25
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Kintara Therapeutics’s price range in the past 12 months?
Kintara Therapeutics lowest stock price was $2.70 and its highest was $20.00 in the past 12 months.
    What is Kintara Therapeutics’s market cap?
    Currently, no data Available
    When is Kintara Therapeutics’s upcoming earnings report date?
    Kintara Therapeutics’s upcoming earnings report date is Sep 25, 2023 which is in 109 days.
      How were Kintara Therapeutics’s earnings last quarter?
      Kintara Therapeutics released its earnings results on May 11, 2023. The company reported -$1.94 earnings per share for the quarter, missing the consensus estimate of -$0.1 by -$1.84.
        Is Kintara Therapeutics overvalued?
        According to Wall Street analysts Kintara Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Kintara Therapeutics pay dividends?
          Kintara Therapeutics does not currently pay dividends.
          What is Kintara Therapeutics’s EPS estimate?
          Kintara Therapeutics’s EPS estimate is -$0.18.
            How many shares outstanding does Kintara Therapeutics have?
            Kintara Therapeutics has 1,692,175 shares outstanding.
              What happened to Kintara Therapeutics’s price movement after its last earnings report?
              Kintara Therapeutics reported an EPS of -$1.94 in its last earnings report, missing expectations of -$0.1. Following the earnings report the stock price went down -6.745%.
                Which hedge fund is a major shareholder of Kintara Therapeutics?
                Currently, no hedge funds are holding shares in KTRA


                Kintara Therapeutics Stock Smart Score

                Not Ranked
                This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                Learn more about TipRanks Smart Score

                Company Description

                Kintara Therapeutics

                DelMar Pharmaceuticals, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. It pipeline includes the VAL-083. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.


                Top 5 ETFs holding KTRA

                Currently, no data available
                Please return soon. This page is being updated.
                Up to five ETFs with an Outperform Smart Score that hold KTRA. The ETFs are listed according to market value of KTRA within the ETF


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Adamis Pharma
                Agile Therapeutics
                Aptose Biosciences
                Arrowhead Pharmaceuticals

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis